Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections. (June 2018)

• Record Type: Journal Article
• Authors: McLaughlin, Milena M.; Miglis, Cristina; Skoglund, Erik; Wagner, Jamie; Advincula, Maria R.; Scheetz, Marc H.
• Is Part Of: Journal of global antimicrobial resistance. Volume 13(2018)
• Page Start: 261
• Page End: 263
• Publication Date: 2018-06
• Subjects: Carbapenem -- Minimum inhibitory concentration -- MIC -- Mortality -- Gram-negative -- Bloodstream infection; Drug resistance -- Periodicals; Drug resistance -- Periodicals; Drug resistance; Periodicals; 616.9041
• DOI: 10.1016/j.jgar.2018.02.003
• Languages: English
• ISSNs: 2213-7165

Abstract

Highlights: Patients receiving directed therapy were less likely to die, despite elevated carbapenem MICs. No relationship shown between receipt of carbapenem and mortality in patients with carbapenem-resistant Gram-negative BSI. Cefepime or piperacillin/tazobactam first directed therapy was associated with survival. Abstract: Objectives: Carbapenem minimum inhibitory concentration (MICs) are known to predict outcomes for patients with Gram-negative bacteraemia. However, limited data exist on how MICs influence such outcomes when organisms are classified as carbapenem-resistant. The purpose of this study was to evaluate the effect of increasing imipenem/cilastatin MICs on mortality in patients with Gram-negative bloodstream infection (BSI). Methods: Patients with an imipenem/cilastatin-resistant (MIC > 4 mg/L) monomicrobial Gram-negative BSI were eligible for inclusion in the study and were assessed for baseline characteristics, organ function, microbiological data, timing and type of therapeutic treatment, and in-hospital mortality. Results: A total of 62 patients with imipenem/cilastatin-resistant bacterial isolates (MIC > 4 mg/L) were retrospectively studied. Time to event analyses found no difference between patients who received carbapenem therapy and those who did not ( P = 0.10). After adjustment, patients receiving directed therapy were less likely to die (adjusted hazard ratio = 0.35, 95% confidence interval 0.15–0.83; P < 0.01), whereas higher modified Acute Physiology and Chronic Health Evaluation (APACHE) II score and days to positive culture were associated with non-survival. Conclusion: This study did not demonstrate a relationship between receipt of a carbapenem and mortality in patients with carbapenem-resistant Gram-negative BSI.